AbbVie (ABBV) FCF Payout Ratio Growth (3y) (2016 - 2026)
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
FCF Cover Growth (3y) (Qtr) |
| 1 |
Novartis Ag |
107,124,802.25 Bn |
107,124,802.25 Bn |
- |
- |
| 2 |
Eli Lilly |
969.00 Bn |
963.72 Bn |
16.22 Bn |
-18.69% |
| 3 |
Johnson & Johnson |
539.46 Bn |
517.41 Bn |
15.96 Bn |
20.26% |
| 4 |
AbbVie |
376.92 Bn |
367.57 Bn |
10.78 Bn |
9.35% |
| 5 |
Merck |
285.00 Bn |
279.35 Bn |
12.09 Bn |
-49.49% |
| 6 |
Amgen |
177.58 Bn |
165.55 Bn |
5.87 Bn |
-16.50% |
| 7 |
Gilead Sciences |
163.22 Bn |
155.50 Bn |
5.52 Bn |
-10.25% |
| 8 |
Pfizer |
145.86 Bn |
133.09 Bn |
-1.21 Bn |
-67.11% |
| 9 |
Bristol Myers Squibb |
111.90 Bn |
101.44 Bn |
8.07 Bn |
56.25% |
| 10 |
Gsk |
88.34 Bn |
83.66 Bn |
- |
- |
| Date | Value |
| Mar 31, 2026 |
9.35% |
| Dec 31, 2025 |
19.68% |
| Sep 30, 2025 |
9.12% |
| Jun 30, 2025 |
4.94% |
| Mar 31, 2025 |
57.75% |
| Dec 31, 2024 |
-4.89% |
| Sep 30, 2024 |
20.84% |
| Jun 30, 2024 |
40.16% |
| Mar 31, 2024 |
13.32% |
| Dec 31, 2023 |
7.93% |
| Sep 30, 2023 |
-1.53% |
| Jun 30, 2023 |
-10.77% |
| Mar 31, 2023 |
11.50% |
| Dec 31, 2022 |
-12.16% |
| Sep 30, 2022 |
-2.29% |
| Jun 30, 2022 |
-8.71% |
| Mar 31, 2022 |
-0.83% |
| Dec 31, 2021 |
2.17% |
| Sep 30, 2021 |
-4.50% |
| Jun 30, 2021 |
-4.01% |
| Mar 31, 2021 |
3.23% |
| Dec 31, 2020 |
2.31% |
| Sep 30, 2020 |
26.84% |
| Jun 30, 2020 |
27.37% |
| Mar 31, 2020 |
-2.26% |
| Dec 31, 2019 |
-7.79% |
| Sep 30, 2019 |
-19.61% |
| Jun 30, 2019 |
9.32% |
| Mar 31, 2019 |
5.83% |
| Dec 31, 2018 |
-1.33% |
| Sep 30, 2018 |
-6.34% |
| Jun 30, 2018 |
5.30% |
| Mar 31, 2018 |
-6.22% |
| Dec 31, 2017 |
35.09% |
| Sep 30, 2017 |
-187.89% |
| Jun 30, 2017 |
-185.24% |
| Mar 31, 2017 |
-27.02% |
| Dec 31, 2016 |
3.72% |
| Sep 30, 2016 |
21.87% |
| Jun 30, 2016 |
15.97% |
| Mar 31, 2016 |
-7.34% |